The system
How the system worksThe DirectoryDispatchThe LedgerAI modelsAI agentsYour installationThe appThe research libraryWhat changes for your businessUse it from your softwareEverything it can do
Messaging
iMessageWhatsApp
Ads and leads
AdsCreativeLeads
Devices
Devices
Industries
RealtorsRestaurantsHome services
Explore
How it worksPermissions and limitsCompareSet upQuestionsText me

retatrutide glp1 agonists

Evidence is being populated by Grok web

Overview

Evidence is being populated by Grok web search.

References (13)
  1. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...“Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.”
  2. Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...“Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.”
  3. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...“Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.”
  4. Retatrutide-A Game Changer in Obesity Pharmacotherapy“Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...”
  5. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)“The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).”
  6. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)“Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.”
  7. Retatrutide in type 2 diabetes mellitus and obesity: an overview“Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).”
  8. Retatrutide and the Paradigm Shift in Multi-Hormonal ...“Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.”
  9. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes“retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.”
  10. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review“Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.”
  11. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models“Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.”
  12. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)“The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.”
  13. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)“The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.”